Author

Frederick Cohen

Nurix (United States)ORCID 0000-0003-2229-3900Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

Ratul MukerjiiD· 3 shared Arthur Sands· 2 shared Austin Tenn-McClellaniD· 2 shared Brandon J. Bravo· 2 shared Dahlia R. WeissiD· 2 shared Dhwani HariaiD· 2 shared Gwenn M. HanseniD· 2 shared Ryan B. RountreeiD· 2 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Ratul MukerjiORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 4, 2026

Bexobrutideg: A Selective, Catalytic Degrader of Bruton's Tyrosine Kinase Overcomes Inhibitor Resistance and Suppresses Autoantibody-Mediated Disease

Mark Noviski, P Auger, Danielle Bautista…·Frederick Cohen

Bexobrutideg is a BTK degrader that overcomes inhibitor resistance and suppresses autoimmune disease by catalytically degrading BTK.

1 citation

𝕏 PostBluesky

Cell BiologyProceedings of the National Academy of SciencesPeer-reviewedMar 27, 2026

Small-molecule CBLB inhibitor abolishes EGFR ubiquitination, reduces receptor endocytosis and diminishes cell motility signaling

Itziar Pinilla‐Macua, Ratul Mukerji, Frederick Cohen, Alexander D. Sorkin

The paper uses a CBLB inhibitor to show that EGFR ubiquitination is essential for clathrin-mediated endocytosis and cell motility, but not for other downstream signaling pathways.

1 citation

humanproteomics

𝕏 PostBluesky

ImmunologybioRxivPreprintJan 24, 2026

Discovery and characterization of small molecule inhibitors of CBL-B that act as intramolecular glue to enhance T-cell anti-tumor activity

Stefan Gajewski, Asad M. Taherbhoy, Kathleen Boyle…·Frederick Cohen

1 citation

𝕏 PostBluesky